Cullinan Therapeutics Inc (NASDAQ: CGEM) kicked off on Tuesday, up 4.84% from the previous trading day, before settling in for the closing price of $7.44. Over the past 52 weeks, CGEM has traded in a range of $5.68-$17.50.
Healthcare Sector giant saw their annual sales slid by -45.66% over the last five years. While this was happening, its average annual earnings per share was recorded -30.86%. With a float of $36.85 million, this company’s outstanding shares have now reached $59.08 million.
Cullinan Therapeutics Inc (CGEM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cullinan Therapeutics Inc is 37.61%, while institutional ownership is 78.39%. The most recent insider transaction that took place on Oct 28 ’25, was worth 1,391,686. In this transaction 10% Owner of this company bought 165,667 shares at a rate of $8.40, taking the stock ownership to the 8,963,500 shares. Before that another transaction happened on Oct 16 ’25, when Company’s 10% Owner bought 150,000 for $8.86, making the entire transaction worth $1,328,250. This insider now owns 8,765,616 shares in total.
Cullinan Therapeutics Inc (CGEM) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.73 earnings per share (EPS), higher than consensus estimate (set at -0.74) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.89% during the next five years compared to -45.66% drop over the previous five years of trading.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Take a look at Cullinan Therapeutics Inc’s (CGEM) current performance indicators. Last quarter, stock had a quick ratio of 10.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.68, a number that is poised to hit -0.85 in the next quarter and is forecasted to reach -3.16 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Analysing the last 5-days average volume posted by the [Cullinan Therapeutics Inc, CGEM], we can find that recorded value of 0.65 million was better than the volume posted last year of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 36.37%.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 59.63%, which indicates a significant increase from 52.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.65 in the past 14 days, which was higher than the 0.46 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.06, while its 200-day Moving Average is $7.96. Now, the first resistance to watch is $8.04. This is followed by the second major resistance level at $8.28. The third major resistance level sits at $8.68. If the price goes on to break the first support level at $7.41, it is likely to go to the next support level at $7.01. Now, if the price goes above the second support level, the third support stands at $6.77.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
The company with the Market Capitalisation of 460.80 million has total of 59,076K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -167,380 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -50,610 K.
